| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
|
Am J Respir Crit Care Med
|
2007
|
33.18
|
|
2
|
Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association.
|
Am J Respir Crit Care Med
|
1997
|
8.10
|
|
3
|
Anonymous mycobacteria in pulmonary disease.
|
Med Clin North Am
|
1959
|
6.07
|
|
4
|
Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.
|
Thorax
|
2000
|
3.96
|
|
5
|
The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.
|
Am J Respir Crit Care Med
|
2003
|
2.78
|
|
6
|
Nontuberculous mycobacteria in the environment.
|
Clin Chest Med
|
2002
|
2.71
|
|
7
|
The relationship of atypical acid-fast bacteria to human disease; a preliminary report.
|
J Lab Clin Med
|
1954
|
2.66
|
|
8
|
Relationship between airway obstruction and respiratory symptoms in adult asthmatics.
|
Chest
|
1998
|
2.62
|
|
9
|
[Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].
|
Therapie
|
1985
|
2.41
|
|
10
|
Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients.
|
Am J Respir Crit Care Med
|
1996
|
2.30
|
|
11
|
Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey.
|
Int J Tuberc Lung Dis
|
2004
|
2.20
|
|
12
|
Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya.
|
J Clin Microbiol
|
1993
|
2.20
|
|
13
|
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
|
Antimicrob Agents Chemother
|
2006
|
2.14
|
|
14
|
Activity of moxifloxacin against mycobacteria.
|
J Antimicrob Chemother
|
1999
|
1.95
|
|
15
|
The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans.
|
J Antimicrob Chemother
|
1991
|
1.90
|
|
16
|
Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors.
|
Am J Respir Crit Care Med
|
2009
|
1.73
|
|
17
|
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.
|
Antimicrob Agents Chemother
|
2003
|
1.71
|
|
18
|
Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients.
|
Eur Respir J
|
2006
|
1.57
|
|
19
|
Pulmonary infection with mycobacterium xenopi: review of treatment and response.
|
Thorax
|
1984
|
1.50
|
|
20
|
The Index of Nausea, Vomiting, and Retching: a new format of the lndex of Nausea and Vomiting.
|
Oncol Nurs Forum
|
1999
|
1.46
|
|
21
|
Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease.
|
Am J Respir Crit Care Med
|
1999
|
1.43
|
|
22
|
Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
|
Thorax
|
2008
|
1.37
|
|
23
|
Comparative in vitro activity of the new macrolide A-56268 against mycobacteria.
|
Eur J Clin Microbiol
|
1987
|
1.32
|
|
24
|
Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi.
|
Am Rev Respir Dis
|
1981
|
1.32
|
|
25
|
Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex.
|
Clin Infect Dis
|
2000
|
1.24
|
|
26
|
Clinical review of pulmonary disease caused by Mycobacterium xenopi.
|
Thorax
|
1983
|
1.23
|
|
27
|
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
|
Antimicrob Agents Chemother
|
2001
|
1.20
|
|
28
|
Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France.
|
Chest
|
1995
|
1.15
|
|
29
|
Isolation of environmental mycobacteria from clinical specimens in south-east England: 1973-1993.
|
Int J Tuberc Lung Dis
|
1997
|
1.13
|
|
30
|
Fluoroquinolones for the treatment of pulmonary tuberculosis.
|
Drugs
|
2007
|
1.11
|
|
31
|
Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
|
J Infect Dis
|
2003
|
1.08
|
|
32
|
Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus.
|
Clin Infect Dis
|
1996
|
0.95
|
|
33
|
Drug intolerance to high-dose clarithromycin among elderly patients.
|
Diagn Microbiol Infect Dis
|
1993
|
0.95
|
|
34
|
Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results.
|
J Chemother
|
2003
|
0.95
|
|
35
|
Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice.
|
Antimicrob Agents Chemother
|
1994
|
0.89
|
|
36
|
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
|
Int J Antimicrob Agents
|
2003
|
0.86
|
|
37
|
Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France.
|
Thorax
|
2008
|
0.86
|
|
38
|
Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
|
Antimicrob Agents Chemother
|
2004
|
0.85
|
|
39
|
Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review.
|
Int J Tuberc Lung Dis
|
2009
|
0.82
|
|
40
|
Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment.
|
Respir Med
|
2003
|
0.81
|
|
41
|
Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.
|
Antimicrob Agents Chemother
|
2001
|
0.80
|
|
42
|
Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients.
|
J Infect
|
2007
|
0.79
|
|
43
|
In vitro sensitivity of Mycobacterium xenopi to five antibiotics.
|
Pathol Biol (Paris)
|
2002
|
0.78
|
|
44
|
[Pulmonary mycobacteriosis due to Mycobacterium xenopi" in-vitro sensitivity to classical antitubercular agents and clinical development].
|
Acta Clin Belg
|
1996
|
0.77
|